LUND, Sweden, April 28, 2020 /PRNewswire/
-- Immunovia has today published first quarter
interim report for January - March
2020. It is available on Immunovia's website.
"During Q1 2020, Immunovia worked hard and continued to make
great strides towards IMMray™ PanCan-d's launch and the sales start
of the first test for early diagnosis of pancreatic cancer, in
spite of the COVID-19 global pandemic.
Work on the verification study proceeded as planned and we
received all the blood samples from our KOL network. In January,
our commercial team prepared detailed plans for the launch and in
March and April these plans were adapted significantly to
accommodate the COVID-19 situation. This included making in-person
activities, such as conferences and the patient organization
meetings that were canceled, into digital activities, etc.
In January, Immunovia welcomed a new Senior VP Sales NA
(North America), Michael Pettigrew, to the team. Michael brings
with him a very successful track record in product launches and
sales growth in life science, along with unique leadership
qualities. He is an important addition to Immunovia.
Following the end of Q1 2020, we provided an update on the
measures the company has taken and continues to take in order to
support patients, employees and public health initiatives in
response to the COVID-19 pandemic. We also announced other crucial
preparations that Immunovia has made in response to COVID-19, such
as securing inventories of critical consumables, the successful
collection of samples for the verification study including the
reallocation of extra blood samples to the efforts of securing all
samples for the verification study. All this done to facilitate the
uninterrupted continuation towards commercialization start.
We reiterate that Immunovia's R&D laboratories and clinical
laboratory in Lund, along with the
production facilities are fully operational. They all have plans in
place to help sustain operations in these unusual times."
- Excerpt from the CEO Mats
Grahn's comment on the report
First Quarter Interim Report for January -
March 2020 Call Details:
Immunovia invites to a teleconference (in English) for
investors, analysts and media on Tuesday,
April 28th, 2020 at 16:30
CET.
Mats Grahn, CEO will present
Immunovia and comment on the first quarter interim report for the
period January - March 2020 followed
by a Q&A session.
Please call in a few minutes in advance. To attend, please
dial-in at one of the numbers below and provide the conference
code Immunovia to the operator:
Conference Numbers:
Sweden: +46 (0)8-50520424
United Sates: +1-212-999-6659
France: +33-(0)1-7099-4740
Denmark: +45-3271-4573
Germany:
+49(0)-69-7104-45598
Spain: +34-91-788-9854
Netherlands:
+31(0)-20-794-8426
Norway: +47-2-156-3318
Austria: +43(0)12530807
Switzerland:
+41(0)43-456-9986
UK (standard international access): +44(0)20-3003-2666
Conference Code: (to provide to the operator)
Immunovia
Immunovia
Webcast: https://channel.royalcast.com/ webcast /
immunovia / 20200428_1 /
There will be an MP3-file available at Immunovia's webpage
under Investors/Financial Reports
(http://immunovia.com/investors/financial-reports/) for those who
want to listen to the telephone conference afterwards. The file
will be available within two hours after the conference has
ended.
This information is information that Immunovia AB is obliged
to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of
the contact person set out above, at 16:00
CET on April 28, 2020.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently entering the final validation for sales start Q3
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
For more information, please contact:
Julie Silber
Director of Investor Relations
Immunovia
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-reports-first-quarter-interim-report-january---march-2020,c3099480
The following files are available for download:
https://mb.cision.com/Main/13121/3099480/1238185.pdf
|
Release
|